Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2014 - 2020)

Zevra Therapeutics (ZVRA) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $18000.0 in Q4 2020.

• Quarterly Non-Current Deferred Tax Liability fell 96.67% year-over-year to $18000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $18000.0 (down 96.67% YoY) and the FY2020 annual result came in at $18000.0, down 96.67% from the prior year.
• Non-Current Deferred Tax Liability retreated to $18000.0 in Q4 2020, from $540000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $540000.0 in Q4 2019 to a low of $10000.0 in Q4 2018.
• A 5-year average of $183400.0 and a median of $89000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2019 — Non-Current Deferred Tax Liability jumped 5300.0% — and 2020, when it plunged 96.67%.
• Tracing ZVRA's Non-Current Deferred Tax Liability over 5 years: stood at $89000.0 in 2016, then jumped by 192.13% to $260000.0 in 2017, then sank by 96.15% to $10000.0 in 2018, then jumped by 5300.0% to $540000.0 in 2019, then slumped by 96.67% to $18000.0 in 2020.
• The last three Non-Current Deferred Tax Liability figures came in at $18000.0 (Q4 2020), $540000.0 (Q4 2019), and $10000.0 (Q4 2018), per Business Quant data.